{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:05:32Z","timestamp":1784307932879,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bulcan.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:44:34Z","timestamp":1781815474000},"page":"924-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiotoxicit\u00e9 chez les enfants et adolescents atteints de leuc\u00e9mie aigu\u00eb\u00a0: recommandations du Comit\u00e9 leuc\u00e9mies de la Soci\u00e9t\u00e9 fran\u00e7aise de lutte contre les cancers et les leuc\u00e9mies de l\u2019enfant et de l\u2019adolescent (SFCE)"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8440-7299","authenticated-orcid":false,"given":"Manon","family":"Delafoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vincenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aphaia","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Prigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rialland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Thouvenin","family":"Doulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Hauet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde Veneziano","family":"Broccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Rabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyne","family":"Poir\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Dominique","family":"Tabone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedoua","family":"El-Louali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-0898","authenticated-orcid":false,"given":"Paul","family":"Saultier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.03.006_bib0430","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0435","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood.2023019804","article-title":"How I treat long-term survivors of childhood acute leukemia","volume":"143","author":"Saultier","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0440","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0445","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0450","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022\u00a0ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0455","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0460","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archinternmed.2010.233","article-title":"Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study","volume":"170","author":"van der Pal","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0465","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1200\/JCO.2017.76.3920","article-title":"Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention","volume":"36","author":"Armenian","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0470","first-page":"5","article-title":"Use of speckle tracking echocardiography to detect late anthracycline-induced cardiotoxicity in childhood cancer: a prospective controlled cross-sectional study","volume":"54","author":"Amedro","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0475","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0480","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0485","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience","volume":"15","author":"Krischer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0490","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cncr.31065","article-title":"Long-term sequelae in survivors of childhood leukemia with Down syndrome: a childhood cancer survivor study report","volume":"124","author":"Goldsby","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12012-015-9307-1","article-title":"Anthracycline-related cardiotoxicity in patients with acute myeloid leukemia and Down syndrome: a literature review","volume":"16","author":"Hefti","year":"2016","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0500","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0505","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0510","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0515","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ng.3374","article-title":"A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer","volume":"4","author":"Aminkeng","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0520","doi-asserted-by":"crossref","DOI":"10.1080\/17425255.2020.1807937","article-title":"Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer","volume":"16","author":"Petrykey","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0525","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaccao.2023.06.007","article-title":"Gene-level analysis of anthracycline-induced cardiomyopathy\u00a0in cancer survivors: a report From COG-ALTE03N1, BMTSS, and CCSS","volume":"5","author":"Sharafeldin","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0530","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants in SLC28A3\u00a0and UGT1A6\u00a0as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0535","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41397-025-00369-y","article-title":"Influence of genetic biomarkers on cardiac diseases in childhood cancer survivors: a systematic review","volume":"25","author":"Aba","year":"2025","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0540","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/cncr.28256","article-title":"Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia","volume":"119","author":"Lipshultz","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0545","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/tpj.2015.63","article-title":"Polymorphisms of ABCC5\u00a0and NOS3\u00a0genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia","volume":"16","author":"Krajinovic","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0550","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1470-2045(23)00012-8","article-title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"24","author":"Ehrhardt","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0555","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","article-title":"Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity","volume":"5","author":"Feijen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0560","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0565","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26600","article-title":"Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0570","first-page":"18","article-title":"Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study","volume":"10","author":"Camilli","year":"2024","journal-title":"Cardiooncology"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0575","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2014.56.1373","article-title":"Individual prediction of heart failure among childhood cancer survivors","volume":"33","author":"Chow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.bulcan.2026.03.006_bib0580","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2459\/JCM.0000000000000375","article-title":"Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients","volume":"17","author":"Bassareo","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0585","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-014-0085-1","article-title":"Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers","volume":"16","author":"Lipshultz","year":"2014","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0590","first-page":"CD005008","article-title":"Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy","volume":"3","author":"van Dalen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0595","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","article-title":"Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01\u00a0acute lymphoblastic leukemia protocol","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0600","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0605","first-page":"e37308","article-title":"Efficacy of dexrazoxane in cardiac protection in pediatric patients treated with anthracyclines","volume":"15","author":"Rahimi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0610","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0615","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer","volume":"41","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0620","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10554-021-02472-0","article-title":"Detection of doxorubicin-induced cardiotoxicity using myocardial T1\u00a0and T2\u00a0relaxation times in childhood acute lymphoblastic leukemia survivors","volume":"38","author":"Aissiou","year":"2022","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0625","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.19.02856","article-title":"Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: a report from the Children's Oncology Group","volume":"38","author":"Getz","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0630","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4143\/crt.2017.457","article-title":"Risk factor analysis for secondary malignancy in dexrazoxane-treated pediatric cancer patients","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0635","first-page":"CD014638","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0640","doi-asserted-by":"crossref","first-page":"e30690","DOI":"10.1002\/pbc.30690","article-title":"Reply to Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: a position statement on dexrazoxane","volume":"70","author":"Bertorello","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0645","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12962-020-0205-4","article-title":"Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective","volume":"18","author":"Dewilde","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0650","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2352-4642(22)00239-5","article-title":"Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"6","author":"de Baat","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0655","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/(SICI)1096-8652(199811)59:3<246::AID-AJH12>3.0.CO;2-H","article-title":"Coincident acute myelogenous leukemia and ischemic heart disease: use of the cardioprotectant dexrazoxane during induction chemotherapy","volume":"59","author":"Woodlock","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0660","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.20747","article-title":"Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane","volume":"59","author":"Bernitsas","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0665","first-page":"36","article-title":"Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia","volume":"7","author":"Vachhani","year":"2017","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0670","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0675","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/hematology.2021000268","article-title":"Minimizing cardiac toxicity in children with acute myeloid leukemia","volume":"2021","author":"Narayan","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0680","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0685","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2024-205666","article-title":"A phase 3\u00a0randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin (GO) to CPX-351\u00a0with GO\u00a0\u2013\u00a0a report from the Children's Oncology Group","volume":"144","author":"Pollard","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0690","doi-asserted-by":"crossref","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0695","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"2011","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0700","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.phrs.2017.03.016","article-title":"Doxorubicin targets multiple players: a new view of an old problem","volume":"127","author":"Cappetta","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0705","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0710","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(24)00001-9","article-title":"Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors","volume":"25","author":"Leerink","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0715","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0720","first-page":"1372","article-title":"The rationale, indications, safety, and use of statins in the pediatric population","volume":"36","author":"Khoury","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0725","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.3390\/nu14163279","article-title":"The role of nutrition in primary and secondary prevention of cardiovascular damage in childhood cancer survivors","volume":"14","author":"Guida","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0730","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.3390\/curroncol29090500","article-title":"The impact of exercise on cardiotoxicity in pediatric and adolescent cancer survivors: a scoping review","volume":"29","author":"Kendall","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0735","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2018.2254","article-title":"Association of exercise with mortality in adult survivors of childhood cancer","volume":"4","author":"Scott","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0740","first-page":"378","article-title":"Left ventricular longitudinal strain abnormalities in childhood exposure to anthracycline chemotherapy","volume":"11","author":"Rique","year":"2024","journal-title":"Children (Basel)"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0745","doi-asserted-by":"crossref","first-page":"102722","DOI":"10.1016\/j.cpcardiol.2024.102722","article-title":"Prevention of cardiotoxicity in childhood cancer survivors: in physical exercise, we trust","volume":"49","author":"Bucciarelli","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0750","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.20.00418","article-title":"Cost-effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group screening guidelines to prevent heart failure in survivors of childhood cancer","volume":"38","author":"Ehrhardt","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0755","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00246-015-1203-8","article-title":"Abnormal myocardial strain indices in children receiving anthracycline chemotherapy","volume":"36","author":"Pignatelli","year":"2015","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0760","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","article-title":"Advances in multimodality imaging in cardio-oncology: JACC state-of-the-art review","volume":"80","author":"Baldassarre","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0765","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0770","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/echo.13418","article-title":"Medium-term assessment of cardiac function in pediatric cancer survivors. Comparison of different echocardiographic methods, cardiac MRI and cardiac biomarker testing in adolescent cancer survivors","volume":"34","author":"Shah","year":"2017","journal-title":"Echocardiography"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0775","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0780","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0785","first-page":"817","article-title":"Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity","volume":"106","author":"Lambert","year":"2020","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0790","doi-asserted-by":"crossref","first-page":"1221787","DOI":"10.3389\/fcvm.2023.1221787","article-title":"Systolic myocardial function measured by echocardiographic speckle-tracking and peak oxygen consumption in pediatric childhood cancer survivors-a PACCS study","volume":"10","author":"Engan","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0805","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0810","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0815","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/cncr.33292","article-title":"Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort","volume":"127","author":"Dixon","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0820","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0825","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016\u00a0ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0830","first-page":"CD008011","article-title":"Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer","volume":"2016","author":"Cheuk","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0835","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/187152508785909474","article-title":"Anthracycline-induced cardiotoxicity","volume":"6","author":"Ferreira","year":"2008","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0840","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yjmcc.2024.08.003","article-title":"Mechanisms of the septic heart: from inflammatory response to myocardial edema","volume":"195","author":"Fan","year":"2024","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0845","first-page":"1708","article-title":"Clinical analysis of pediatric acute leukemia complicated with septic shock","volume":"30","author":"Liu","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.bulcan.2026.03.006_bib0425","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126002225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126002225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:30:15Z","timestamp":1784305815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126002225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0007455126002225"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.03.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiotoxicit\u00e9 chez les enfants et adolescents atteints de leuc\u00e9mie aigu\u00eb\u00a0: recommandations du Comit\u00e9 leuc\u00e9mies de la Soci\u00e9t\u00e9 fran\u00e7aise de lutte contre les cancers et les leuc\u00e9mies de l\u2019enfant et de l\u2019adolescent (SFCE)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}